Home / Letter From The Editor / Nov. 23, 2019

Nov. 23, 2019

Nov 23, 2019

Last week I mentioned the problems with the TZD’s and cardiovascular health. The uproar that this correlation had was enough to cause the FDA to require cardiovascular studies on all new and future diabetes medications. Many times the pharma companies looked at these studies as an unnecessary hindrance to bringing a new drug to market. However, when it came to the SGLT-2 inhibitors, I am guessing that every one of the companies were happy they had to do the studies and learn the CV positive benefits they could talk about.

This week our Intern, Andrew Daoud, PharmD Candidate, Florida A&M University, has some information on another claim that one of the products can make, that can be life-saving for many of our patients. Click here to find out what the drug is and what its new indication is for




We can make a difference!


Dave Joffe